These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 29462398

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L, Peyrin-Biroulet L.
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M, Sciascia S, Roccatello D, Cuadrado MJ.
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [Abstract] [Full Text] [Related]

  • 8. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [Abstract] [Full Text] [Related]

  • 9. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ, Blokzijl T, Festen EAM, Pham BT, Faber KN, Brouwer E, Dijkstra G.
    PLoS One; 2018 Jun; 13(12):e0208922. PubMed ID: 30533022
    [Abstract] [Full Text] [Related]

  • 10. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Trystram N, Abitbol V, Tannoury J, Lecomte M, Assaraf J, Malamut G, Gagnière C, Barré A, Sobhani I, Chaussade S, Amiot A.
    Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
    [Abstract] [Full Text] [Related]

  • 11. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
    Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, Plasencia C, Balsa A, Llinares-Tello F, Rosas J, Torres N, Martínez A, Nagore D.
    Ann Rheum Dis; 2016 Sep; 75(9):1693-6. PubMed ID: 26965981
    [Abstract] [Full Text] [Related]

  • 12. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW.
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
    Smits LJT, van Esch AAJ, Derikx LAAP, Boshuizen R, de Jong DJ, Drenth JPH, Hoentjen F.
    Inflamm Bowel Dis; 2019 Jan 01; 25(1):172-179. PubMed ID: 29947795
    [Abstract] [Full Text] [Related]

  • 17. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
    Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A.
    Inflamm Bowel Dis; 2021 Jan 19; 27(2):182-189. PubMed ID: 32083291
    [Abstract] [Full Text] [Related]

  • 18. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
    Gros B, Plevris N, Constantine-Cooke N, Lyons M, O'Hare C, Noble C, Arnott ID, Jones GR, Lees CW, Derikx LAAP.
    United European Gastroenterol J; 2023 Mar 19; 11(2):179-188. PubMed ID: 36802176
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.